Gene transfer engineering for astrocyte-specific silencing in the CNS. by Merienne, N. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but does not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Gene transfer engineering for astrocyte-specific silencing in the 
CNS. 
Authors: Merienne N, Delzor A, Viret A, Dufour N, Rey M, Hantraye P, 
Déglon N 
Journal: Gene therapy 
Year: 2015 Oct 
Volume: 22 
Issue: 10 
Pages: 830-9 
DOI: 10.1038/gt.2015.54 
 
  1 
Gene transfer engineering for astrocyte-specific silencing in the 
CNS 
 
Merienne Nicolas, MSc 1,2,5, Delzor Aurélie, PhD 3,4,5, Viret Amaya, MSc 1,2, Dufour 
Noëlle, MSc 3,4, Rey Maria 1,2, Hantraye Philippe, PhD 3,4 and Déglon Nicole, Pr 1,2* 
 
1Laboratory of Cellular and Molecular Neurotherapies (LCMN), Department of Clinical 
Neurosciences, Lausanne University Hospital, Lausanne, Switzerland; 2LCMN, Neuroscience 
Research Center (CRN), Lausanne University Hospital, Lausanne, Switzerland, 
3Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Institute of 
Biomedical Imaging (I2BM), Molecular Imaging Research Center (MIRCen), Fontenay-aux-
Roses, France; 4CNRS-CEA URA2210, Fontenay-aux-Roses, France; 5These authors 
equally contributed to these work.  
 
Running title: Cell-type specific gene silencing in the CNS 
 
*Correspondence should be addressed to N.D. (nicole.deglon@chuv.ch)  
Nicole Déglon 
Lausanne University Hospital (CHUV) 
Pavillon 3, Avenue de Beaumont 
1011 Lausanne 
Switzerland 
Phone: +41 21 314 21 20 
Fax: +41 21 314 08 24 
 
Number of words: 7023 (including figures) 
  2 
ABSTRACT 
Cell-type specific gene silencing is critical to understand cell functions in normal and 
pathological conditions, in particular in the brain where strong cellular heterogeneity exists. 
Molecular engineering of lentiviral vectors (LV) has been widely used to express genes of 
interest specifically in neurons or astrocytes. However, we show that these strategies are not 
suitable for astrocyte-specific gene silencing due to the processing of shRNA in a cell. Here, 
we develop an indirect method based on a tetracycline-regulated (Tet) system to fully restrict 
shRNA expression to astrocytes. The combination of Mokola-G envelope pseudotyping, 
glutamine synthetase (GS) promoter and two distinct miRNA target sequences provides a 
powerful tool for efficient and cell-type specific gene silencing in the CNS. We anticipate our 
vector will be a potent and versatile system to improve the targeting of cell populations for 
fundamental as well as therapeutic applications.  
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INTRODUCTION 
Cell-type specific overexpression or silencing of a gene of interest has been used to dissect 
cellular functions and to assess the therapeutic benefits of gene therapy. In vivo, this has 
been investigated in transgenic animals or following the intracerebral injection of viral 
vectors, and may involve tissue-specific promoters to control transgene expression 1, 2. The 
injection of viral vectors provides an efficient gene transfer system irrespective of the species 
considered, age of the animals and the targeted organ 3. Moreover, viral vectors are simple 
to produce 4. Among them, lentiviral vectors (LV) have a large cloning capacity, high 
transduction efficiency and can be engineered to restrict transgene expression to particular 
cell subtypes 5, 6. The pseudotyping of LV particles with the glycoprotein G of the vesicular 
stomatitis virus (VSV-G) results in efficient neuronal targeting with ubiquitous promoters 7 
whereas both neurons and astrocytes are transduced when LV is pseudotyped with the 
glycoprotein G of the Mokola virus (MOK-G) 8. Tissue-specific promoters may be used to 
restrict further transgene expression to a particular cell subpopulation. However, these 
transcriptional regulatory elements are still poorly characterized and there are few examples 
of tightly regulated transgene expression involving viral vectors 9, 10. Regulation involving 
miRNA has been explored as an alternative strategy 11. For CNS applications, we 
demonstrated that four copies of the neuron-specific miRNA-124 target sequence (miR124T) 
in a Mokola-pseudotyped LV (MOK/LV) specifically suppresses transgene expression in 
neurons and not in astrocytes 12. We also showed that this vector efficiently silences the 
GLAST gene, expressed mainly in astrocytes 12. However, during small-hairpin RNA 
(shRNA) processing and maturation, miRT sequences should be cleaved from the mature 
shRNA; therefore, we hypothesized that this vector would not be suitable to induce glial-
specific loss-of-function phenotypes of ubiquitously expressed genes. We sought to 
overcome this issue to investigate further the physiological functions and contribution of glial 
cells to neurodegenerative diseases. Therefore, we indirectly regulated the expression of 
shRNA with a tetracycline-regulated (Tet) system in a single MOK/LV. The combination of 
this Tet-regulated system with a tissue-specific promoter and miRNA regulation leads to the 
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robust silencing of gene expression in glial cells. This approach may be potentially extended 
to other cell populations for which cell-type specific promoters and miRT are available and 
provides a powerful system to restrict transgene expression in distinct cell populations. 
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RESULTS 
 
A miRNA detargeting approach is not suitable for LV constitutively expressing shRNA  
We hypothesized that a classical detargeting approach is not appropriate for a cell-type 
specific gene silencing due to the processing of the shRNA (Fig. 1C). This was confirmed by 
injecting a VSV-G pseudotyped LV expressing a miR30-embedded shRNA targeting the GFP 
(shGFP) under the control of the phosphoglycerate kinase 1 (PGK) promoter with 4 copies of 
the fully homologous miR124T sequence (PGK-miR30-shGFP-miR124T, hereafter called 
VSV/LV-shGFP-miR124T) into the striatum of BAC-Drd2-eGFP transgenic mice expressing 
the enhanced green fluorescent protein (GFP) in striatal neurons of the indirect pathway 1,7, 
13. As a negative control, we used an LV expressing an shRNA showing no homology with 
the mouse transcriptome (VSV/LV-shUNIV) and as a positive control, we used a LV 
expressing the shGFP without miR124T sequences (VSV/LV-shGFP). We also co-injected a 
VSV/LV expressing DsRed under the PGK promoter to visualize the injection site and 
facilitate post-mortem analysis (VSV/LV-DsRed; Fig. 1A). Pictures of the infected areas show 
the extensive loss of GFP expression in animals injected with the positive control expressing 
the shGFP in neurons (VSV/LV-shGFP), whereas this is not observed in the shUNIV group 
(Fig. 1A-B). DsRed fluorescence in the GFP-negative area confirms that the silencing is not 
due to toxicity or cell death induced by LV injection. GFP expression was significantly 
impaired in animals that received the VSV/LV-shGFP-miR124T. Quantification of the volume 
of GFP silencing shows that there is no statistical difference between VSV/LV-shGFP-
miR124T and VSV/LV-shGFP groups (Fig. 1B). This shows that despite the presence of the 
miR124T sequences on the vector, GFP silencing is occurring in neurons. Thus, these 
results demonstrate that a direct coupling of the miRT sequence to the miRNA-embedded 
shRNA is not suitable for astrocyte-type specific gene silencing, probably due to the 
cleavage of miRT sequences from shRNA during miRNA processing (Fig. 1C). 
 
Development of an alternative strategy: a tetracycline-regulated (Tet) system 
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In order to circumvent this limitation, we indirectly controlled the tissue-specific expression of 
shRNA with the tetracycline-regulated transactivator (tTA/S2). In this system, shRNA 
expression is driven from a Tet-responsive element (TRE) fused with the minimal 
cytomegalovirus promoter (CMVmin), and the tTA/S2 is under the control of a polymerase II 
promoter and miR124T sequences (Fig. 1D). When the LV transduces neurons, the 
endogenous miR124 recognizes the miR124T present at the 3’ UTR of the tTA/S2 and 
induces the degradation of the tTA/S2 mRNA. Thus, the shRNA is not expressed in neurons. 
In contrast, when the LV infects astrocytes, the tTA/S2 is expressed and binds to the TRE to 
induce shRNA expression. 
 
Effect of astrocytic promoters on LV tropism 
We tested different astrocytic promoters as a first step towards the establishment of an 
astrocyte-specific silencing system. We injected MOK/LV expressing the nuclear DsRed 
(DsRednuc) under the control of the human excitatory amino acid transporter 1 (EAAT1), the 
human glial fibrillary acidic protein (gfaABC1D), or the rat glutamine synthetase (GS) 
promoter into the striatum of adult BAC-GLT1-eGFP transgenic mice expressing GFP in 
astrocytes 14. As a control, we used a MOK/LV expressing DsRednuc under the ubiquitous 
cytomegalovirus (CMVa) promoter. We used the neuronal marker NeuN and GFP-positive 
astrocytes to determine the tropism of the vectors (Fig. 2A). All promoters, including the 
CMVa promoter, gave rise to strong astrocytic expression of the transgene, with at least 88% 
of the DsRednuc-positive cells co-localized with GFP and NeuN/DsRednuc double-stained 
cells were scarce (Fig. 2B).  
 
Combined effects of an astrocytic promoter and miR124T detargeting on LV tropism 
We sought to improve further the tissue-specificity and eliminate residual transgene 
expression in neurons (up to 12%); therefore, we added four copies of the miR124T 
sequence to the 3’ UTR of the DsRednuc reporter gene. We pseudotyped the CMVa, 
EAAT1, gfaABC1D and GS-DsRednuc-miR124T LVs with MOK-G and injected them into the 
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striatum of GLT1-eGFP mice. The animals were killed three weeks later and sections were 
processed for NeuN immunostaining. Quantitative analysis of the co-localization between 
DsRednuc and either GFP or NeuN staining revealed that the miR124T sequence improved 
the specificity of vector containing the GS promoter, whereas the tropism was not modified in 
the other conditions (Fig. 2C-D). In particular, GS and gfaABC1D promoters lead to more 
than 95% of astrocyte-specificity and could thus be of interest for the design of astrocyte-
specific vectors. Qualitative observations during image acquisition indicate that the GS 
promoter is more efficient, in agreement with the expression profile of gfap (coding for GFAP 
protein) and glul (coding for GS protein) genes from the Allen Brain Atlas microarray data 
(http://www.brain-map.org) 15 (Supplementary Fig. 1). Thus, considering the astrocytic 
tropism and level of expression, we chose the GS promoter to pursue the study. 
 
Functionality and tropism of the Tet-regulated LV 
To establish the functionality and tropism of the Tet-regulated system with cell-type specific 
promoters and detargeting strategy, we integrated the GS and the miR124T into a single 
tetracycline-regulated lentiviral backbone pseudotyped with the MOK-G envelope 16 
expressing a nuclear GFP cassette (AcGFPnuc) (Supplementary Fig. 2A). In BAC-GLAST-
DsRed transgenic mice expressing the DsRed gene specifically in astrocytes 14, the reporter 
gene was expressed in astrocytes, with 75.2 ± 3.5% of AcGFPnuc-positive cells co-localized 
with astrocytic markers with the GS-miR124T vector (Supplementary Fig. 2B). This shows 
that, despite a lower astrocytic tropism than constitutive vectors (Figure 2), the Tet-regulated 
backbone is functional in the mouse striatum and provides an appropriate vector for further 
development.  
 
Efficiency and specificity of the Tet-regulated LV-shRNA 
Figure 2 and Supplementary Figure 2 demonstrate that transgene overexpression under the 
GS promoter without miR124T sequences or in the Tet-regulated system leads to a strong 
astrocytic tropism. To demonstrate the added value of a Tet-regulated system for cell-type 
specific gene silencing, we integrated a miR30-embedded shGFP in constitutive and Tet-
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regulated backbones (MOK/LV-Tet-shGFP-miR124T, Tet-shGFP; MOK/LV-GS-shGFP, GS-
shGFP) (Fig. 3A). We co-injected these vectors with a VSV/LV-DsRed into GLT1-eGFP mice 
and examined brain sections 3 weeks post-transduction to determine the efficiency of 
silencing. Mosaic acquisitions indicate that the silenced area is equivalent between inducible 
and constitutive systems (Fig. 3B). However, the mean fluorescence intensity in the silenced 
area with the constitutive system is higher than with the Tet-regulated construct, 
demonstrating that silencing with the Tet-regulated system is more potent (Fig. 3C). This 
shows that, despite a strong astrocytic tropism for both vectors, shGFP expression in a Tet-
regulated backbone provides a more powerful silencing efficiency, which is probably due to 
the amplification loop of the system leading to greater transgene expression and confirm the 
important added value of the Tet system 16.  
To quantify the specificity of the Tet-regulated system, and in particular potential residual 
silencing activity in neurons, we used a bicistronic LV coexpressing mCherry and GFP in 
neurons 17 (VSV-G/LV-mCherry-GFP) (Fig. 3D). We measured GFP and mCherry 
fluorescence intensity in individual neurons and determined a GFP/mCherry ratio: if residual 
GFP silencing occurs in neurons, the ratio will be low. We co-injected the MOK/LV-Tet-
shGFP-miR124T (Tet-shGFP-miR124T) or MOK/LV-Tet-shUNIV-miR124T (Tet-shUNIV-
miR124T) vectors with the neurotropic VSV-G/LV-mCherry-GFP into the striatum of C57Bl/6 
mice and analyzed fluorescence intensity 3 weeks post-injection. Pictures were acquired for 
each channel and the mean fluorescence intensity per cell (MFI/cell) was quantified for both 
GFP and mCherry. The GFP/mCherry ratio for the negative control (Tet-shUNIV-miR124T) 
was arbitrarily set at 1. The GFP/mCherry ratio in the Tet-shGFP-miR124T group was 
significantly lower than that of the Tet-shUNIV-miR124Tgroup, demonstrating a residual GFP 
silencing in neurons (Fig. 3D). Together with data from Supplementary Fig. 2, these results 
demonstrate that the transgene expression in Tet-regulated LV is powerful but not tightly 
restricted to astrocytes and thus needs to be improved.  
 
Combination of miR9*T-miR124T sequences for efficient and specific silencing in 
astrocytes  
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Previous studies have demonstrated the benefit of combining two distinct miRT sequences to 
suppress transgene expression in a specific cell population 17. These effects depend on 
miRNA levels and activity, but additional factors influence the extent of suppression 17. We 
therefore chose a second miRNA, the miR9* to improve the cell-type-specific expression in 
astrocytes 17 and demonstrated the functionality of the construct in a MOK-G/LV 
(Supplementary Fig. 3).  
We then generated a MOK/LV-Tet-shGFP-miR9*T-miR124T vector (Tet-shGFP-miR9*T-
miR124T) and injected it into the striatum of BAC GLT1-eGFP transgenic mice to assess the 
silencing efficiency (Fig. 4A). As negative control, we used a MOK/LV-Tet-shUNIV-miR9*T-
miR124T (Tet-shUNIV-miR9*T-miR124T) vector. We co-injected the vector expressing 
DsRed into neurons (VSV/LV-DsRed; Fig. 4B) to visualize the infected area to guide 
quantifications. Brains were collected 3 weeks post-transduction and the efficiency of the 
GFP silencing was determined by measuring the volume of GFP loss in the striatum. 
Pictures show extensive GFP loss around the DsRed-positive infected area (Fig. 4B); GFP 
was silenced in more than 1mm3 of striatum in animals infected with the Tet-shGFP-miR9*T-
miR124T construct, whereas GFP was not silenced in the animals that received the Tet-
shUNIV-miR9*T-miR124T vector (Fig. 4C). This result demonstrates the silencing efficacy of 
the Tet system regulated by multiple miRT sequences. 
As a final validation of the construct, we assessed the specificity of the vector with the 
bicistronic VSV/LV-mCherry-GFP system. We used the Tet-shUNIV-miR9*T-miR124T vector 
as a negative control and an shGFP expressed from the PGK promoter (PGK-shGFP) as a 
positive control. We co-injected viral vectors into the striatum of C57Bl/6 mice and collected 
brains 3 weeks post-transduction. The fluorescence intensity of the mCherry was used as a 
reference to determine the GFP/mCherry ratio in each group (Fig. 4D-E). As expected, the 
GFP/mCherry ratio was significantly lower with the positive control (PGK-shGFP, neuronal 
silencing) than with the negative control (Fig. 4D-E). The GFP/mCherry ratio was not 
statistically different between the Tet-shUNIV-miR9*T-miR124T and the Tet-shGFP-miR9*T-
miR124T-infected groups (Fig. 4D-E), whereas a significant difference was observed 
between shGFP and shUNIV groups containing only the miR124T (Figure 3D). The 
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difference between these two constructs demonstrates that the combination of multiple miRT 
sequences with cell-type specific promoters in Tet-regulated system results in a strong 
astrocyte-specific gene silencing.  
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DISCUSSION 
The advent of whole-transcriptome profiling provides unprecedented opportunity to study 
gene expression and cellular functions in the brain. However, new experimental systems are 
required to take into account the diversity of CNS cell-types, unravel the contributions of 
individual subpopulations and characterize further the diversity of cellular phenotypes in 
physiological and pathological conditions. The overexpression or silencing of genes are 
prototypical experimental paradigms to address these questions. Currently, in vivo astrocyte-
specific loss of function studies rely on the development of knockout mice or take advantage 
of mice expressing Cre recombinase under the control of cell-type specific promoters to 
knock-out floxed genes 2. Recently, various fragments of the GFAP promoter have been 
used as transcriptional control elements in viral vectors to restrict transgene expression to 
astrocytes 10, 18. AAVs have been used for astrocyte-specific gene overexpression. This has 
involved the use of specific serotypes and astrocytic promoters. However, they have not yet 
been used for cell-type specific silencing and the small packaging size of AAVs limits the 
integration of complex and large expression cassettes in astrocytes 10, 19. In addition, the 
choice of LV envelope could have an impact on the viral vector tropism. We used MOK-G/LV 
due to their natural preferential tropism for astrocytes 12, 20. If VSV-G/LV have the potential to 
transduce astrocytes 21, the combination of VSV-G/LV envelope, PGK promoter and 
miR124T was not sufficient to fully restrict transgene expression to astrocytes 12.  
In the present study, we developed a new LV, which enables local, cell-type specific, and 
tightly controlled silencing in vivo. We were able to achieve astrocyte-specific silencing with 
this vector as a proof-of-principle. We combined a single Tet-regulated lentiviral vector, 
integrating an indirect miRT detargeting strategy, with Mokola pseudotyping and an 
astrocytic promoter to control RNAi activity and avoid transgene expression in unwanted 
cells.  
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We tested three astrocytic promoters in MOK-G pseudotyped LV. We used a reporter gene 
to facilitate the characterization of the tropism in the striatum of adult mice. All promoters, 
including the CMV promoter, resulted in more than 90% of reporter gene expression in 
astrocytes, with or without the insertion of the miR124T. Similar results have been reported 
with MOK-G pseudotyped LV expressing GFP and glial cell line-derived neurotrophic factor 
(GDNF) under the CMV promoter 20. In contrast, in VSV-G pseudotyped LV, the CMV 
promoter leads to neuronal transgene expression with limited transcriptional activity in 
astrocytes, suggesting that the choice of the envelope has an impact on the tropism of LV-
CMV 7, 22.  
Another important factor in the selection of a tissue-specific promoter is its transcriptional 
activity. Cell-type specific promoters are often associated with weak transgene expression, 
as demonstrated for the EAAT1 promoter 12. The GS and GFAP proteins are produced in 
astrocytes and synthesized to a small extent in neurons 23, 24. Microarray data in the mouse 
striatum indicate that the GS promoter has a higher transcriptional activity than the GFAP 
promoter, confirming the utility of this promoter for gene transfer applications 15. Additional 
expression profile studies are needed to characterize promoters with a higher transcriptional 
activity.  
When we transferred the system into the single Tet-regulated vector, the residual activity in 
neurons was significantly higher than in the constitutive vector. This phenomenon has been 
observed both for reporter gene overexpression and for gene silencing (Supplementary Fig. 
2 and Fig. 4). This phenomenon reflects the leakiness of the Tet-regulated system and is 
coherent with previous studies 16, 25. Indeed, the tetracycline system can lead to residual 
activity in the “off” stage when two independent vectors are used 25, 26. Incorporation of the 
entire system into a single LV and modifications of the central polypurine tract (cPPT) and 
woodchuck hepatitis virus (WHV) elements drastically reduce the basal expression 25. 
Despite a significant improvement with this combination, residual activity is high when a 
tissue-specific promoter regulates the expression of the transactivator 25. One additional 
hypothesis to explain this leakiness is that the tetracycline system creates an amplification 
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loop which enhances transgene expression 26, 27. This is conceivable because GS 
transcriptional activity in the constitutive system was not associated with detectable 
transgene expression in neurons, whereas in the inducible system, residual reporter gene 
expression was detected.  
We combined the miR124T sequence with a second miRT to provide additive or 
synergistic effects to overcome the limitation of residual transgene activity in unwanted cells 
17. Brown and collaborators elegantly demonstrated the potency of this strategy when miR 
target sequences of highly expressed, cell-type specific miRNAs are integrated into the 3’ 
UTR of a gene 11, 28. In our study, we selected two miRNAs known to be highly active in 
neurons; miR124 and miR9* 29-31. The efficiency of miRNA regulation is correlated with the 
number of target sequences and the restriction of transgene expression to one particular cell 
type is facilitated by the use of target sequences for two miRNAs; therefore, we used four 
copies of each fully homologous miR124T and miR9*T to ensure a rapid and efficient 
detargeting effect 32. The insertion of these sequences into the Tet-regulated vector 
completely blocked residual expression in neurons.  
This new LV provides a powerful and flexible system for astrocyte-specific gene 
silencing in adult animals and is complementary to experimental design based on transgenic 
mice. In addition, this system can be adapted to generate vectors suitable for silencing in 
other subpopulations of cells in the brain or peripheral organs, by changing the promoter and 
miRT sequences depending on the target cell population. Current limitations for the 
generalization of the approach is the restricted choice of miRT sequences and tissue-specific 
promoters due to the lack of cell-type specific miRNA expression profiles in adult or 
developing animals and poor characterization of transcriptional regulatory elements. Ongoing 
international projects should greatly improve the situation in the future 15, 33, 34. This LV gene 
transfer will facilitate in vivo silencing and offers new opportunities for local, cell-type specific, 
and regulated silencing. Thus, this tool will facilitate the study of gene candidates in various 
cellular pathways, reveal cell-autonomous functions, identify processes that depend on cell-
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cell interactions in neurodegenerative diseases, and uncover the contribution of specific 
subpopulations of cells in pathological conditions.  
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MATERIALS AND METHODS 
Plasmids 
Constitutive silencing 
The miR30-embedded shGFP (GeneArt, Invitrogen, Cergy-Pontoise, France) 35, 36 was 
inserted into a SIN-PGK-GDNF-WPRE lentiviral plasmid containing the woodchuck post-
regulatory element (WPRE) and encoding the Glial Cell line-Derived Neurotrophic factor 
(GDNF) under the control of the mouse phosphoglycerate promoter (PGK) 13. The resulting 
plasmid SIN-PGK-miR30-shGFP was further modified to restrict transgene expression to 
astrocytes. For this, four fully homologous copies of the neuronal microRNA124 target 
sequence (miR124T) were added at the 3’ end of the transgene (miRBase, Eurofins MWG 
Operon, Ebersberg, Germany) 5, 28. As a negative control, a lentiviral vector encoding the 
miR30-shUNIV sequence was used (pCCL-cPPT-PGK-miR30-shUNIV) (kindly provided by 
Prof. Naldini, Milano, Italy; sequence: GGTATCGATCACGA GACTAGC) 36. 
 
Astrocyte-specific promoters and miRT detargeting strategies 
The DsRednuc and mCherry reporter genes (Clontech, Saint-Germain-en-Laye, France) 
were used to assess LV tropism (SIN-promoter-DsRednuc-WPRE or SIN-promoter-mCherry-
WPRE). The following promoters were used for astrocyte-specific expression:  a 2 kb 
fragment of the human excitatory amino acid transporter 1 promoter (EAAT1; GeneArt, 
Invitrogen, Cergy-Pontoise, France; GenBank AF448436.1, nt: 1 to 2051) 37; the shortest 
form (681 bp) of the human glial fibrillary acidic protein (gfaABC1D; courtesy of Dr. Brenner 
through the support of NIH grant NS39055, Birmingham, AL, USA; GenBank NG_008401.1, 
nt: 3292 to 3793 and 4916 to 5094); 38 and the 432 bp of the rat glutamine synthetase 
promoter (GS; GenBank M91651.1, nt: 2111 to 2543), which was amplified from rat genomic 
DNA with the following primers: 5’-CACCATCGATGGCTCGCTCAACAAAGGGTAA-3’ and 
5’-GGATCCCTCG GCTGTGGAGGGTTGCGG-3’ (GenBank M91651.1, nt: 1 to 2132 with a 
CACC flanking sequence for oriented cloning, and nt: 2524 to 2543 for forward and reverse 
primers, respectively) 23. As a control, we used the 710 bp of the human cytomegalovirus 
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promoter (CMVa, Clontech, Saint-Germain-en-Laye, France; GenBank JQ302818.1, nt: 209 
to 918). 
Astrocyte-specific transgene expression was obtained by subcloning miR124T 5, and miR9*T 
(miRBase, AGAAACCAATAGATCGACATACTATTCGAAAGAAACCAATAGATC 
GACAT, GeneArt, Invitrogen, Regensburg, Germany) into LV transfer plasmids to obtain: 
SIN-CMVa-DsRednuc-WPRE-miR124T, SIN-EAAT1-DsRednuc-WPRE-miR124T, SIN-
gfaABC1D-DsRednuc-WPRE-miR124T, SIN-GS-DsRednuc-WPRE-miR124T, SIN-GS-
mCherry-WPRE-miR124T, SIN-rGS-mCherry-WPRE-miR9*T and SIN-GS-mCherry-WPRE-
miR9*T-miR124T. 
 
Constitutive and tetracycline-regulated LV gene silencing  
A cassette encoding the nuclear-localized green fluorescent protein (AcGFPnuc; Clontech, 
Saint-Germain-en-Laye, France) was inserted into the pCCL-MCS-cPPT-CMVb-tTA/S2-
WPRE-TRE-SIN (kindly provided by Prof. Naldini, Milano, Italy) 16. Two promoters were used 
to control tTA/S2 expression to generate vectors for astrocyte-specific silencing: CMVb 
(GenBank AY468486.1, nt: 2020 to 2624) or GS (GS; GenBank M91651.1, nt: 2111 to 2543) 
alone or in combination with four copies of the miR124T sequence. The final constructs 
were: pCCL-AcGFPnuc-cPPT-CMVb-tTA/S2-WPRE-TRE-SIN, pCCL-AcGFPnuc-cPPT-
CMVb-tTA/S2-WPRE-miR124T-TRE-SIN and pCCL-AcGFPnuc-cPPT-GS-tTA/S2-WPRE-
miR124T-TRE-SIN.  
Silencing efficiency was determined with the pCCL-AcGFPnuc-cPPT-GS-tTA/S2-WPRE-
miR124T-TRE-SIN, in which the AcGFPnuc was replaced with miR30-embedded shUNIV or 
shGFP. Silencing efficiency was compared with constitutive system by replacing the PGK 
promoter into the SIN-cPPT-PGK-miR30-shGFP with the rGS promoter (SIN-cPPT-rGS-
miR30-shGFP).  
The final Tet-regulated construct was constructed by inserting four copies of the miR9*T 
sequence were added upstream from the miR124T sequence to generate the final products: 
pCCL-miR30-shUNIV-cPPT-GS-tTA/S2-WPRE-miR9*T-miR124T-TRE-SIN and pCCL-
miR30-shGFP-cPPT-GS-tTA/S2-WPRE-miR9*T-miR124T-TRE-SIN.  
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The specificity of the Tet-regulated construct was evaluated with the bicistronic vector 
expressing both GFP and mCherry (pCCL-mCherry-CMVmin-hPGK-eGFP-WPRE-SIN kindly 
provided by Prof Naldini, Milano, Italy; Brown et al, 2007).  
LV expressing the reporter genes DsRed or blue fluorescent protein (DsRed and 
BFP, Clontech, Saint-Germain-en-Laye, France) under the control of the mouse PGK 
promoter (PGK; from -430 to +74 relative to the transcriptional start site (TSS); GenBank 
M18735.1 nt: 423 to 931) were used to facilitate the visualization of the infected area.  
 
Lentiviral vector production 
Lentiviral vectors were produced in Human Embryonic Kidney 293T cells (HEK 293T, 
mycoplasma negative, ATCC, LGC Standards GmbH, Germany), with the four-plasmid 
system, as described previously 39. The HIV-1 vectors were pseudotyped with either the 
vesicular stomatitis virus glycoprotein G (VSV-G) or the Mokola lyssavirus glycoprotein G 
(MOK-G) 12. Viruses were concentrated by ultracentrifugation and resuspended in 
phosphate-buffered saline (dPBS, Gibco, Life Technologies, Zug, Switzerland) with 1% 
bovine serum albumin (BSA, Sigma-Aldrich, Buchs, Switzerland). The viral particle content of 
each batch was determined by p24 antigen enzyme-linked immunosorbent assay (p24 
ELISA, RETROtek; Kampenhout, Belgium). The stocks were finally stored at -80°C until use. 
 
Animals 
Adult males and females BAC-GLT1-eGFP, BAC-GLAST-DsRed (courtesy of Prof. J. 
Rothstein, Baltimore, MD, USA) 14, Tg(Drd2-EGFP)S118Gsat/Mmnc (BAC-Drd2-eGFP, 
Mutant Mouse Regional Resource Center, USA) 1 and C57Bl/6 (Charles River, France) 
between 3 and 10 months old were used for in vivo experiments. The animals were housed 
in a temperature-controlled room (22°C±1°C) and maintained on a 12 h light/night cycle. 
Food and water were available ad libitum. All experimental procedures were performed in 
strict accordance with the recommendations of the European Community directive 
(86/609/EEC) and Swiss legislation about the care and use of laboratory animals. All 
experiments involving animals were performed once. Sample size was chosen to take into 
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account statistical variability due to surgical procedure based on previous studies 36. No 
randomization was used to determine group inclusion and experiments were not performed 
in blind.  
 
Stereotaxic procedure 
 Concentrated viral stocks were thawed on ice and resuspended by repeated 
pipetting. Low doses of LV were used (100 and 200 ng p24 in PBS/1% BSA) to facilitate the 
analysis of the tropism and avoid saturation of transcriptional activities. For co-transduction 
with viral vectors expressing fluorescent proteins, between 50 and 100 ng of LV-DsRed/BFP 
were added to the viral vector of interest.  
Mice were anesthetized by intraperitoneal injection of a mixture of 100 mg/kg 
ketamine (Ketasol, Graeub, Bern, Switzerland) and 10 mg/kg xylazine (Rompun, Bayer 
Health Care, Uznach, Switzerland). Suspensions of lentiviral vectors were injected into the 
mouse striatum with a 34-gauge blunt-tip needle linked to a Hamilton syringe by a 
polyethylene catheter. Stereotaxic coordinates were: anteroposterior +1 mm from bregma; 
mediolateral +/-1.8 mm and dorsoventral -3.5 mm from the skull, with the tooth bar set at -
3.3 mm. Mice received a total volume of 3 µl of the vector preparation, administered at a rate 
of 0.2 µl/min. At the end of injections, needles were left in place for 5 min before being slowly 
removed. The skin was sutured with 6-0 Prolene suture (B-Braun Mediacal SA, Sempach, 
Switzerland) and mice were allowed to recover on a heating mat. Number of animals 
(biological replicates) used in each experiments is indicated in the Figure legends. The only 
exclusion criterion was a problem encountered during the injection procedure.  
 
Brain processing 
Two or three weeks post-lentiviral injection, the animals were killed by an overdose of 
sodium pentobarbital (NaCl, B-Braun, Sampach, Germany; Esconarkon, Streuli, Uznach, 
Germany) and transcardially perfused with a 4% paraformaldehyde solution (4% PFA; 
Electron Microscopy Sciences, Hatfield). The brains were removed and post-fixed in 4% PFA 
for 12 h and then cryoprotected in 20% sucrose / PBS for 3 h and in 30% sucrose / PBS for 
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24 h. A sledge microtome with a freezing stage at -30 °C (Leica SM2010R, Biosystems 
Switzerland, Nunningen, Switzerland) was used to cut coronal sections between 20 and 
30 µm thickness. Slices throughout the entire striatum were collected and stored in tubes as 
free-floating sections in anti-freeze solution (18% sucrose, 0.25% sodium azide, ethylene 
glycol and sodium phosphate 50mM, pH = 7.4). Slices were then stored at -20°C.  
 
Immunohistochemistry 
The following primary antibodies were used: mouse monoclonal anti-neuronal nuclei 
antibody (NeuN, 1/200; MAB377, Millipore, Molsheim, France); rabbit polyclonal anti-
neuronal nuclei antibody (NeuN, 1/1000, ABN78, Millipore, Zug, Switzerland) and goat 
polyclonal anti-mCherry antibody (mCherry, 1/1000, AB0040-200, SicGen, Lisboa, Portugal). 
For antibodies produced in mice, immunostaining was performed with the mouse-on-mouse 
detection kit (Vectashield M.O.M kit, Vector Lab Inc, Clinisciences, Nanterre, France). For 
other antibodies, free floating slices were rinsed 3 x 10 minutes in PBS (Laboratorium Dr 
Bichsel AG, Interlaken, Switzerland), followed by the saturation of non-specific sites in PBS 
containing 10% BSA (Sigma-Aldrich, Buchs, Switzerland) and 0.1% Tritton X100 (Fluka, 
Sigma-Aldrich, Buchs, Switzerland) for 1h at room temperature under agitation. Primary 
antibodies were incubated overnight at 4°C under agitation. Slices were rinsed 3 x 10 
minutes in PBS and incubated with the secondary antibodies for 1h at room temperature 
under agitation. The following secondary antibodies were used: anti-mouse IgG AlexaFluor 
350 (1/500, A10035, Life Technologies, Saint Aubin, France), donkey anti-goat IgG 
AlexaFluor 568 (1/1000, A11057, Invitrogen, Life Technologies, Zug, Switterland). Slices 
were then rinsed 3 x 10 minutes in PBS, followed by mounting with Vectashield mounting 
medium for fluorescence with DAPI (Vector Lab Inc, Burlingame, CA, USA). 
Image acquisition and quantitative analysis 
For co-localization studies, images of the sections labeled for GLT1-eGFP and NeuN 
were acquired with a 40x objective on a Leica DM6000B microscope (Leica, Nanterre, 
France) equipped with an automated motorized stage and image acquisition software 
(MorphoStrider, Explora nova, La Rochelle, France). The number of DsRed2nuc-NeuN-
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positive cells and DsRed2nuc-GLT1-eGFP-positive cells were quantified by ImageJ software 
(http://rsb.info.nih.gov/ij/, NIH, Bethesda, MD, USA) to determine the percentage of 
astrocytes or neurons expressing the transgene.  
For the GFP silencing studies, mosaic images were acquired with an Olympus BX 40 
microscope at a 10x objective (Olympus, Le Mont-sur-Lausanne, Switzerland), with 
Morphostrider software (Explora Nova, La Rochelle, France). The area of GFP loss was 
measured with Mercator Pro software (Explora Nova, La Rochelle, France) along the entire 
infected area to determine the volume of GFP silencing. Mosaic images for silencing 
efficiency comparisons between constitutive and Tet-regulated systems were acquired with 
the Zeiss AxioVision at 10x (Zeiss, Carl Zeiss Microscopy GmBH, Göttingen, Germany). 
Mosaic images for the evaluation of silencing efficiency of the MOK/LV-shGFP-miR9*T-
miR124T were acquired with the Zeiss AxioScan Z1 (Zen software, Zeiss, Carl Zeiss 
Microscopy GmBH, Göttingen, Germany). 
Mean fluorescence intensity quantifications for the silencing efficiency comparison 
between Tet-regulated and constitutive system were done based on acquisitions performed 
with a 40x oil immersion objective with an inverted confocal microscope Zeiss LSM 510 
META (LSM software, Carl Zeiss Microscopy GmBH, Göttingen, Germany). Regions at the 
periphery of the transduced area were delineated with ImageJ software and the mean 
fluorescence intensity normalized on the area of the region was determined for each groups. 
For the quantification of the bicistronic vector, images were acquired with a 63x oil 
immersion objective with an inverted confocal microscope Zeiss LSM 510 META (LSM 
software, Carl Zeiss Microscopy GmBH, Göttingen, Germany). The mCherry fluorescence 
intensity is used as a reference to determine the GFP expression level (measurement of 
mCherry/GFP fluorescence ratio). Acquisition parameters of the Zeiss LSM 510 META and 
of the camera were maintained constant for all the groups. Neurons expressing both GFP 
and mCherry were delimited and the mean fluorescence intensity of each channel was 
measured with the ImageJ software.  
 
Statistical analysis 
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Data are presented as the mean ± standard error of the mean (SEM). Statistical 
analysis was carried out with Statistica software (Statsoft, Maisons-Alfort, France) and the 
threshold of significance was maintained at p < 0.05, without correction for multiple 
comparisons. All statistical analysis are two-sided tests.  
Statistical analyses to compare two independent groups were done with paired or 
unpaired Student t test. When more than two groups were compared, one-way ANOVA with 
a Newman-Keuls post-hoc was used. A one-way ANOVA with a Newman-Keuls post-hoc 
was performed on Arcsine transformed data to analyze the percentages of infected neurons 
and astrocytes. Normality of the data and equality of variances between groups was 
assessed as a prerequisite to perform statistical analysis.  
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FIGURE LEGENDS 
Figure 1: A miRNA detargeting approach is not suitable for LV constitutively 
expressed shRNA  
(a): VSV/LV-shUNIV (n = 4), VSV/LV-shGFP-miR124T (n= 4) and VSV/LV-shGFP (n = 4) 
were co-injected with VSV/LV-DsRed into the striatum of BAC Drd2-eGFP transgenic mice to 
evaluate the hypothesis that the miR124T is cleaved from the shRNA. Confocal pictures 
show GFP loss in LV-shGFP-miR124T and LV-shGFP groups surrounded by DsRed 
fluorescence, revealing that GFP loss is not due to neuronal death following LV injection. 
Scale bar = 50µm 
(b): Silencing efficiency was quantified based on the volume of GFP fluorescence. One-way 
ANOVA and Newman-Keuls post-hoc analysis reveals efficient GFP silencing in both LV-
shGFP and LV-shGFP-miR124T but no differences between LV-shGFP and LV-shGFP-
miR124T. * p < 0.05, results are presented as mean ±	SEM. 
(c): Schematic representation of the hypothesis of miR124T cleavage. LVs enter both 
neurons and astrocytes, with a preferential tropism for astrocytes depending on the 
envelope. Transcription of the miR30-embedded shGFP and natural processing releases the 
20 bp shGFP without the miR124T sequences, which impairs detargeting in neurons and 
results in GFP silencing in both cell populations.  
(d): Schematic representation of the alternative strategy based on the Tet-regulated LV. LV 
expressing the Tet-regulated system enters neurons and astrocytes. In astrocytes, the 
expressed tTA/S2 dimerizes and recognizes the TRE to induce shGFP expression, leading 
to GFP silencing. In neurons, the residual transcription of the astrocytic promoter generates a 
tTA/S2 mRNA containing the miRT sequences. Hybridization of the endogenous neuronal 
miRNA degrades the tTA/S2 mRNA, which results in the loss of shGFP expression in 
neurons. 
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Figure 2: Effect of astrocytic promoters and miR124T sequences on LV tropism 
(a) and (c): Microscope acquisition of BAC GLT1-eGFP transgenic mice infected with LV 
expressing DsRednuc under the CMVa, EAAT1, gfaABC1D or GS promoter alone (a) or in 
combination with four copies of the miR124T (c). Acquisition parameters were not 
maintained constant between the groups because of differences in strength of promoter 
activity. Scale bar = 10µm 
(b): Colocalization between DsRednuc and eGFP positive-astrocytes or NeuN-positive 
neurons for the CMVa (n = 5), EAAT1 (n = 5), gfaABC1D (n = 6) and GS (n = 6) groups. One-
way ANOVA on arcsine-transformed values for all the groups and Newman-Keuls post-hoc 
analysis reveals statistical differences only between CMVa and GS groups. * p < 0.05, 
results are presented as mean ±	SEM. 
(d): Percentage of DsRednuc positive-cells colocalizing with NeuN or eGFP in the CMVa-
miR124T (n = 4), EAAT1-miR124T (n = 5), gfaABC1D-miR124T (n = 6) and GS-miR124T (n= 
6) groups. One-way ANOVA reveals no statistical differences between the groups, results 
are presented as mean ±	SEM. 
 
Figure 3: Efficiency and specificity of the Tet-regulated LV expressing shRNA 
(a): Schematic representation of the GS-shGFP (left) and Tet-shGFP (right) constructs.  
(b): Mosaic acquisitions of the infected area for the GS-shGFP (left), Tet-shGFP (middle) and 
a non-injected groups (right). Pictures show an extended loss of GFP signal in both 
constitutive and Tet-regulated system with no major differences between the two groups.  
(c): Quantification of the fluorescence intensity of the infected area in GS-shGFP (n = 3) and 
Tet-shGFP (n = 3). Confocal acquisitions were performed at the periphery of the infected 
area to determine the differential silencing efficiency between the two groups. Mean GFP 
fluorescence intensity shows that the GFP silencing is more efficient with the Tet-regulated 
system than with the constitutive construct. Paired Student t test, ** p < 0.01, results are 
presented as mean ±	SEM.  
(d): Schematic representation of the bicistronic vector expressing both GFP and mCherry in 
neurons under the PGK or CMVmin promoters. High magnification pictures were acquired at 
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constant acquisition parameters. The mean fluorescence intensity per cell was calculated for 
shGFP-miR124T (n = 4) and shUNIV-miR124T (n = 5) groups 2 weeks post-transduction. 
Unpaired Student t-test reveals that the GFP/mCherry ratio in the shGFP-miR124T group is 
significantly lower (11%) than that of the shUNIV-miR124T group, revealing residual GFP 
silencing in neurons. Data are represented as mean ±	SEM. * p < 0.05 
 
Figure 4: Efficient, astrocyte-specific gene silencing by the combinatorial effect of 
miR9*T-miR124T detargeting 
(a): Schematic representation of the final Tet-regulated LV for astrocyte-specific gene 
silencing. In this version of the vector, tTA/S2 expression is regulated by the GS promoter 
and four copies of both miR9*T and miR124T sequences. 
(b): Brains were processed three weeks post-transduction and the GFP silencing volume 
was quantified. Slice scanning and confocal acquisitions show extensive GFP loss in the 
hemisphere treated with the Tet-shGFP-miR9*T-miR124T but not in the control Tet-shUNIV-
miR9*T-miR124T. Scale bar = 50µm 
(c): Paired Student t-test reveals that the volume of GFP silencing in the Tet-shGFP-miR9*T-
miR124T (n = 7) is significantly higher than in the Tet-shUNIV-miR9*T-miR124T (n = 7) 
group. Results are presented as mean ± SEM , *** p < 0.001. 
(d): Neurons were infected with the Tet-shUNIV-miR9*T-miR124T (n = 8), Tet-shGFP-
miR9*T-miR124T (n = 10) or PGK-shGFP (n = 10) vector in combination with the bicistronic 
vector expressing both GFP and mCherry to assess astrocytic specificity of the viral 
construct. High magnification confocal pictures at constant acquisition parameters were 
performed to quantify the mean fluorescence intensity per cell. Scale bar = 20µm 
(e): One-way ANOVA and Newman-Keuls post-hoc analysis reveal that the GFP/mCherry 
ratio of both Tet-shUNIV-miR9*T-miR124T and Tet-shGFP-miR9*T-miR124T groups are 
significantly different from that of the PGK-shGFP group. There was no significant difference 
between Tet-shUNIV-miR9*T-miR124T and Tet-shGFP-miR9*T-miR124T groups, 
suggesting that residual GFP silencing does not occur in neurons in the Tet-shGFP-miR9*T-
miR124T group. Results are presented as mean ± SEM, ** p < 0.01. 
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SUPPLEMENTARY INFORMATIONS 
 
Supplementary Figure 1: Differential expression of gfap and glul in the mouse striatum 
(a): Tridimensional visualization of the gfap and glul (GS) expression in MRI coordinate 
space from Allen Brain Atlas (Allen Institute for Brain Science, Seattle (WA), Available from: 
http://www.brain-map.org, reconstructed with Brain Explorer 2 software, available from: 
http://human.brain-map.org/static/brainexplorer), 15. Expression levels from in-situ 
hybridization for gfap (up, red dots) and glul (bottom, cyan dots) were aligned on mouse MRI 
data on the coronal and sagittal plans. Dots size and density suggest a stronger expression 
of glul compared with gfap.  
(b): Microarray expression data from striatum samples for gfap and glul taken from the Allen 
Brain Atlas reveals a strong differences of expression between gfap and glul in the mouse 
striatum. Scale is log2 transformed, results are presented as mean ± SEM. 
 
Supplementary Figure 2: Functionality and tropism of the Tet-regulated LV 
(a): Schematic representation of the Tet-regulated LV expressing AcGFPnuc. For this 
experiment, the GS promoter and four copies of the miR124T sequence regulate the tTA/S2. 
AcGFPnuc expression is driven from the TRE.  
(b): Brains were processed three weeks post-transduction and colocalization between 
AcGFPnuc and DsRed-positive astrocytes or NeuN-positive neurons was quantified for the 
CMVb, CMVb-miR124T and GS-miR124T groups (n = 4 for all groups). One-way ANOVA 
reveals no statistical differences between the groups. Results are presented as mean ± 
SEM. 
 
 
Supplementary Figure 3: Efficient neuronal detargeting with a miR9*T sequence 
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(a): The detargeting efficiency of miR124T and miR9*T sequences was compared with LV 
expressing mCherry in a constitutive system. High magnification confocal acquisitions of the 
mCherry-positive area were performed for the analysis. Scale bar = 20µm 
(b): Quantification of the number of mCherry-positive cells colocalizing with the eGFP-
positive astrocytes. Percentages were transformed with the arcsine transformation to perform 
statistical analysis. Unpaired Student t-test reveals no statistical differences between the 
MOK/LV-GS-mCherry-miR124T (GS-miR124T, n = 6) and MOK/LV-GS-mCherry-miR9*T 
(GS-miR9*T, n = 4) groups, suggesting that miR9*T sequences can be used for neuronal 
miRT detargeting. Results are presented as mean ± SEM. 
 
 
 
Figure 1 
Figure 2 
Figure 3 
Figure 4 
Figure S1 
Figure S2 
Figure S3 
